We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/8/2016 12:41 | I'm in for a few of these today! Hoping the company succeeds very much. | moormoney | |
30/7/2016 20:56 | A few months old, but still of interest: "Jim Mellon-backed biotech to join Aim SalvaRX working on treatments using T-cells to attack tumours MARCH 21, 2016 by: Andrew Ward, Pharmaceuticals Correspondent An experimental cancer drug discovered at Oxford university is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group." P.S. Please note the following thread which may be of interest: "THE REVERSE TAKEOVERS & SHELLS THREAD (RTO)" | hedgehog 100 | |
05/7/2016 18:15 | Is this a dead cat bounce heading for a fall down towards 6p... | halfpenny | |
05/7/2016 18:14 | Why buy this stock...... Nobody has provided a strong case.....they received grants but can they deliver.. | halfpenny | |
04/7/2016 14:43 | This is the second leg down so will we have a third, remember they did buy 3 Leg !! 6p getting closer, let's see.... | rocketblast | |
02/7/2016 18:14 | you need to value it based on facts. Revenue: 0 Risk: High Rewards: Unknown result may get in at 6p for the risk....im waiting...no hurry remember... never catch a falling knife especially one with double sharp sides..ouch | halfpenny | |
28/6/2016 14:10 | is it worth it at 24p? clearly wasn't at 34p. | runwaypaul | |
09/5/2016 12:05 | It is worth adding to your shareholdings here. A major breakthrough will see the company's value multiply many times. | kingston78 | |
08/5/2016 15:59 | SalvRx owns 10% of Intensity Therapeutics .... Looking forward to tomorrow and whether and if so how the market reacts to this article. Interesting that there were buyers around last week at the full offer price - which might indicate there really aren't any sellers | edcrane | |
08/5/2016 14:28 | Intensity Therapeutics; | doodlebug4 | |
21/4/2016 15:37 | The CEO is over from America next week and we should see some share price action. | wiseacre | |
05/4/2016 10:24 | dropping like stone right now. sucking em in@36 spitting em out @28 AT man stripping the Bid | runwaypaul | |
31/3/2016 14:06 | With so little stock out there you need to be buying at the base levels | kmann | |
30/3/2016 10:52 | The share price is moving up towards the 35.5 p subscription price, which should act as a base. This company has great potential and I always follow the man who leads from the front. A successful businessman will always make his new ventures successful. He has his reputation to protect. | kingston78 | |
30/3/2016 09:22 | One to buy before the crowd. Blockbuster potential. | kmann | |
29/3/2016 21:28 | VELA took its stake up from .64% to over 3% last week unless I'm mistaken? DC | daicaprice | |
22/3/2016 13:01 | As stig says, cashed up to Phase II. They can attract research funding too. IP can be worth a pretty penny, ask the makers of asprin, viagra etc. Thats where were heading. Reducing cancer to a chronic condition. Always a premium for IP. ARM another good example. | kmann | |
22/3/2016 12:24 | they have cash of c£3.5m market cap over £12.5m | soul limbo | |
22/3/2016 12:11 | Oxford Uni not as hot as Cambridge I think | the stigologist | |
22/3/2016 10:53 | I have a feeling some of JMs mates are heavy backers too, the kind who know what success looks and tastes like. The concept here is good, and Oxford University have enough clout too. | kmann | |
22/3/2016 10:14 | Better be quick then...http://techno | hitch19 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions